{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":8},"studies":[{"active":true,"description":"A Phase 2/3 Open Label Randomized Study of\nTelisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally\nAdvanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer\nAfter Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713","eudractNumber":"2025-521124-29-00","id":11332,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT07155187","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2026-03-02T10:56:01+01:00","shortTitle":"Abbvie M25-713 AndroMETa-Lung-713","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<p align=\"left\" class=\"Text\">Long Term\nFollow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (PAVO)</p>","eudractNumber":"2014-001673-14","id":1805,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT02445222","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2016-05-11T11:16:30+02:00","shortTitle":"CAR-T Long Term Follow Up (LTFU) Study, CCTL019A2205B (PAVO)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus<br />Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in<br />Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small<br />Lymphocytic Lymphoma","eudractNumber":"2024-517131-52-00","id":11276,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT06943872","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-10-31T08:53:02+01:00","shortTitle":"CELESTIAL-RR CLL (BGB-11417-303)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"Ziel dieser multizentrischen, randomisierten, doppelblinden, aktiv-komparator-kontrollierten, adaptiven Phase-2/3-Studie ist die Entwicklung einer neuartigen Kombinationsimmuntherapie, EIK1001 + Pembrolizumab, f&#252;r die Behandlung des Melanoms","eudractNumber":"2024-512659-19-00","id":11739,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"}],"nctNumber":"NCT06697301","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-11-26T11:42:59+01:00","shortTitle":"EIK1001-006","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Eine multizentrische, randomisierte, offene Phase-2/3-Studie zur \nUntersuchung von Zanzalintinib versus Everolimus bei Patienten mit \nvorbehandelten, nicht resezierbaren, lokal fortgeschrittenen oder \nmetastasierten neuroendokrinen Tumoren.&#160;","eudractNumber":"2025-521043-20-00","id":11695,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":"NCT06943755","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2026-03-19T08:34:51+01:00","shortTitle":"Exelixis XL092-311","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Long-Term Follow up Protocol for subjects treated with gene-modified T Cells<br />","eudractNumber":"2017-001465-24","id":5382,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT03435796","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2019-01-10T13:02:46+01:00","shortTitle":"GC-LTFU-001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND \nCEMIPLIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH \nRESECTABLE STAGE III AND IV MELANOMA","eudractNumber":"2022-502825-17-00","id":9882,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"LAG-3","id":"mt_39"}],"nctNumber":"NCT06190951","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-10-09T09:45:47+02:00","shortTitle":"REGENERON / R3767-ONC-2208","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"},{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"An International Clinical Program for the diagnosis and Treatment of children, adolescents and young adults with ependymoma","eudractNumber":"2013-002766-39","id":2398,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT02265770","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2020-06-18T10:07:43+02:00","shortTitle":"SIOP Ependymoma II","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]},"initialUrl":"/api/studies?lang=de&page=0&pfs=ph_8&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":8,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 2/3 Open Label Randomized Study of\\nTelisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally\\nAdvanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer\\nAfter Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713\",\"name\":\"Abbvie M25-713 AndroMETa-Lung-713\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11332\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<p align=\\\"left\\\" class=\\\"Text\\\">Long Term\\nFollow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (PAVO)</p>\",\"name\":\"CAR-T Long Term Follow Up (LTFU) Study, CCTL019A2205B (PAVO)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/1805\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus<br />Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in<br />Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small<br />Lymphocytic Lymphoma\",\"name\":\"CELESTIAL-RR CLL (BGB-11417-303)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11276\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Ziel dieser multizentrischen, randomisierten, doppelblinden, aktiv-komparator-kontrollierten, adaptiven Phase-2/3-Studie ist die Entwicklung einer neuartigen Kombinationsimmuntherapie, EIK1001 + Pembrolizumab, f&#252;r die Behandlung des Melanoms\",\"name\":\"EIK1001-006\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11739\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Eine multizentrische, randomisierte, offene Phase-2/3-Studie zur \\nUntersuchung von Zanzalintinib versus Everolimus bei Patienten mit \\nvorbehandelten, nicht resezierbaren, lokal fortgeschrittenen oder \\nmetastasierten neuroendokrinen Tumoren.&#160;\",\"name\":\"Exelixis XL092-311\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11695\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Long-Term Follow up Protocol for subjects treated with gene-modified T Cells<br />\",\"name\":\"GC-LTFU-001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/5382\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND \\nCEMIPLIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH \\nRESECTABLE STAGE III AND IV MELANOMA\",\"name\":\"REGENERON / R3767-ONC-2208\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9882\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"An International Clinical Program for the diagnosis and Treatment of children, adolescents and young adults with ependymoma\",\"name\":\"SIOP Ependymoma II\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/2398\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=1&pfs=ph_8\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}